Evidence map›Paper›PMID 33949300›Full record

SynthesisThe Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques2022

Guillain Barre Syndrome as a Complication of COVID-19: A Systematic Review.

Mohammad Aladawi, Mohamed Elfil, Baha Abu-Esheh, Deaa Abu Jazar, Ahmad Armouti, Ahmed Bayoumi, Ezequiel Piccione

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. The spectrum of anti-GQ1B antibody syndrome: beyond Miller Fisher syndrome and Bickerstaff brainstem encephalitis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19.Archives de pediatrie : organe officiel de la Societe francaise de pediatrie · 2023
    Review
  17. Review
  18. Immune-Mediated Neuropathies: Pathophysiology and Management.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Coronavirus Disease: Subacute to Chronic Neuroimaging Findings.Neuroimaging clinics of North America · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Mohammad AladawiDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Mohamed ElfilDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0002-1125-2946
Baha Abu-EshehDepartment of Neurology, Mercy Hospital, Oklahoma City, Oklahoma, USA.
Deaa Abu JazarDepartment of Neurology, University of Texas Medical Branch - Galveston, Galveston, Texas, USA.
Ahmad ArmoutiDepartment of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Ahmed BayoumiDepartment of Neurology, Yale University, New Haven, Connecticut, USA.
Ezequiel PiccioneDepartment of Neurological Sciences, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn January 2020, the first case of Guillain Barre syndrome (GBS) due to COVID-19 was documented in China. GBS is known to be postinfectious following several types of infections. Although causality can only be proven through large epidemiological studies, we intended to study this association by a thorough review of the literature.

methodsWe searched PubMed, EMBASE, and Google scholar and included all papers with English or Spanish full text and original data of patients with GBS and recent COVID infection. Variables of interest were demographics, diagnostic investigations, and the latency between arboviral and neurological symptoms. Further variables were pooled to identify GBS clinical and electrophysiological variants, used treatments, and outcomes. The certainty of GBS diagnosis was verified using Brighton criteria.

resultsWe identified a total of 109 GBS cases. Ninety-nine cases had confirmed COVID-19 infection with an average age of 56.07 years. The average latency period between the arboviral symptoms and neurologic manifestations for confirmed COVID-19 cases was 12.2 d. The predominant GBS clinical and electromyography variants were the classical sensorimotor GBS and acute demyelinating polyneuropathy respectively. Forty cases required intensive care, 33 cases required mechanical ventilation, and 6 cases were complicated by death.

conclusionsStudies on COVID-19-related GBS commonly reported sensorimotor demyelinating GBS with frequent facial palsy. The time between the onset of infectious and neurological symptoms suggests a postinfectious mechanism. Early diagnosis of GBS in COVID-19 patients is important as it might be associated with a severe disease course requiring intensive care and mechanical ventilation.

Indexed as

Bell PalsyCOVID-19Guillain-Barre SyndromeElectromyographyHumansMiddle AgedSARS-CoV-2COVID-19GBSGuillain Barre syndromeMFSMiller Fisher syndromeSARS-CoV2

Identifiers

PMID33949300
PMCPMC8267336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.